Manuscript of Recent Bioanalysis Symposium in UK Available from MDS Pharma Services

(Montreal, Canada. May 19, 2004) — MDS Pharma Services, a leading provider of innovative drug discovery and development solutions, held the latest symposium in its Scientific Leadership Series, "Current Trends in Bioanalysis," March 4 and 5, at its recently-opened bioanalysis laboratory in the Sittingbourne Research Centre in Kent, UK. A manuscript of the symposium, which featured pharmaceutical industry thought leaders from throughout the United Kingdom, Europe and the United States, is now available on CD-Rom at no charge and may be requested via email to symposium@mdsps.com.

"Our Scientific Leadership symposium in Sittingbourne confirms our continuing commitment to scientific excellence and to providing our colleagues in the UK and in Europe with the information, technologies and geographic presence that will help them bring drugs to market faster and more efficiently," said James Hulse, Ph.D., senior vice president and general manager, Bioanalysis.

Squires said the company is geared up to implement the new cardiovascular safety guidelines, with services available from discovery through regulatory approval, including specific capabilities in pharmacology (hERG K+ ion channel assay), drug safety assessment (Patch-Clamp or Electrophysiology; Action Potential Duration (APD), hemodynamics and telemetry) and early clinical research (telemetry, PK/PD and pertinent drug-class expertise). In addition, MDS Pharma Services' Centralized ECG services include:

• Keynote presentation -- "Current and Future Trends in Drug Metabolism," Dr. Dennis Smith, Pfizer UK;
• "Bioanalytical Mass Spectrometry History, Recent Developments and Future Directions," Dr. Thomas Covey, MDS Sciex;
• "Turbulent Flow Chromatography Applied to Bioanalysis," Tony Edge, Cohesive Technologies, Inc.;
• "Regulated Quantitative Bioanalysis - Possible Futures?," Dr. Neil Spooner, Worldwide Bioanalysis, DMPK;
• "Mass Spectrometry and Proteomics," Dr. Matthius Mann, Professor, Center for Experimental Bioinformatics, University of Southern Denmark;
• "Gene Expression Signatures of Breast Cancer Cells Procured by LCMS as Novel Biomarkers for Predicting Clinical Outcome," Dr. James L. Wittliff, Professor, James Graham Brown Cancer Center, University of Louisville;
• "Immunogenicity of Protein-Based Therapeutics," Dr. George Scott, MDS Pharma Services;
• "Outsourcing in Context and New Models for the Future," Michael Edwards, Accenture Health and Lifesciences - London;
• "Bioanalytical Outsourcing," David Muirhead, Pfizer UK, PGRD.

MDS Pharma Services offers a full spectrum of resources to meet the drug discovery and development needs of the pharmaceutical and biotechnology industries. With numerous facilities strategically located around the world, the company applies advanced scientific and technological expertise to each stage of the drug discovery and development process - early stage: lead optimization, pre-IND research and development, pharmaceutical and biopharmaceutical development, early clinical research (bioequivalence, phases I-IIa) and bioanalysis; and late stage: global clinical development (phases IIb-IV) and central lab. For more information, visit MDS Pharma Services' Web site at www.mdsps.com.

MDS Pharma Services is part of MDS Inc. (TSX: MDS; NYSE: MDZ), an international health and life sciences company. In many of its products and services, it is among the largest and most respected companies in the world. MDS is focused on enhancing the health of people around the world. It does this by providing laboratory testing, imaging products and research services to speed discovery and development of new drugs, therapy systems for planning and delivery of cancer treatments, analytical instruments to assist in the development of new drugs, and medical/surgical supplies. MDS employs more than 10,000 highly skilled people in its global operations on five continents. Detailed information about the company is available at the MDS Web site at www.mdsintl.com or by calling 1-888-MDS-7222, 24 hours a day.

# # #

For further information, please contact Kevin Langin, MDS Pharma Services, 621 Rose Street, Lincoln, Neb., Tel: (402) 476-2811, and visit our Web site at www.mdsps.com.